Biotechnology and the Patent System
Balancing Innovation and Property Rights

  • Title:

    Biotechnology and the Patent System
  • Format:

    Paperback
  • Paperback Price:

    25.00
  • Paperback ISBN:

    978-0-8447-4256-4
  • Paperback Dimensions:

    6'' x 9''
  • 128 Paperback pages
  • Buy the Book

Click here to view Biotechnology and the Patent System as an Adobe PDF.

 

American patent law has reached an unprecedented crossroads, prodded by a landmark Supreme Court decision this spring and the prospect of sweeping new federal legislation this fall. At this critical time, Biotechnology and the Patent System: Balancing Innovation and Property Rights provides a timely look at the complex issues involved in making patent law for cutting-edge high-tech industries such as the biotechnology and computer software sectors.

Barfield and Calfee clearly explain arcane issues of patent law and the tremendous effect that they can have on our economy, our technological progress, and our health. As Congress considers sweeping changes to the patent law, this book is a timely evaluation of the strengths and weaknesses of the current system and the risk of overly aggressive reform.

Biotechnology and the Patent System analyzes the role of intellectual property protection in biomedical research, one of America’s leading growth industries. Barfield and Calfee explore ways in which patent law fosters future research and venture capital investment; they also evaluate whether the current system could potentially impede genomic research and the development of new treatment and diagnostic tools. With these competing concerns in mind, the authors evaluate proposals currently under discussion in Congress (S 1145 and HR 1908) and how they would affect biotechnological innovation and, in turn, the quality of our health care.

These proposals have created passionate disagreements among affected industries, with technology and software companies pressing for fundamental reforms that would shift the balance of power from patent holders to patent challengers. Biotechnology, pharmaceutical, and manufacturing firms, as well as large research universities and venture capital associations, contend that the reform proposals are too radical and would undercut U.S. international competitiveness and retard innovation.

In just a few decades, the U.S. biotechnology industry has gone from a handful of startups to a major industry with a market capitalization of $400 billion and payroll of over 130,000 people. Yet the industry’s growth can’t mask a simple fact of life for most biotech companies: it is difficult to make a profit because of the high costs, high risks, and extremely long development times in developing biotechnological therapies and devices. In 2006, the industry as a whole lost $5 billion.

Potential changes to existing patent law would further complicate these issues; Barfield and Calfee show how some proposed changes to patent law would make it difficult to attract the venture capital that small biotech firms need to develop commercially viable products. They also show that the problems often cited by current critics of patent law are rendered moot by a series of self-correcting remedies and “working solutions” to allow for the responsible sharing of biomedical research.

Even so, Barfield and Calfee acknowledge the need for measured reforms of our current patent system that would allow people to challenge patent applications through administrative procedures without protracted and expensive litigation. They call for Congress to move cautiously and build upon consensus proposals, mindful of the unintended or negative consequences of previous reform efforts. Reform proposals that would garner widespread support include the implementation of a first-to-file patent system and the creation of a system to ensure all patent applications are published within eighteen months.

Claude Barfield is a resident scholar at AEI.

John E. Calfee is a resident scholar at AEI.

 

Praise for Biotechnology and the Patent System

"Barfield and Calfee have produced a lucid, dispassionate, and exceptionally thorough review of the issues, politics, and legislative aspects of patent reform. This up-to-date study reviews not just the shortcomings of the U.S. Patent Office and current patenting procedures but also the key issues in the patent reform legislation moving through the current Congress. Unlike advocacy tracts prepared by individual interest groups, their analysis shows how the interests of key groups, such as the biotechnology and software industries, as well as university researchers, differ."

--Kenneth W. Dam, professor emeritus of American and foreign law and senior lecturer, University of Chicago; senior fellow, The Brookings Institution

"This study is an objective, unbiased, and well-reasoned examination of many of the difficult issues that must be addressed as we attempt to reform and modernize our nation¹s patent laws. This is an excellent contribution to the dialogue on patent reform and to the ongoing congressional deliberations."

--Don Martens, chair, Task Force on Patent Law Reform, Intellectual Property Law Section,
American Bar Association

"Barfield and Calfee have written a little book with big implications. They sound an important alarm: public health advances will stagnate if incremental innovation in medical technology goes unrewarded with patent protection. Their advice and guidance must be heeded as we move forward into the heated debate over patent law and real health care reform."

--Peter Pitts, president, Center for Medicines in the Public Interest; former associate commissioner, Food and Drug Administration (2002-04)



Click here to view the press release for Biotechnology and the Patent System.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Claude
Barfield

 

John E.
Calfee
  • Economist John E. Calfee (1941-2011) studied the pharmaceutical industry and the Food and Drug Administration (FDA), along with the economics of tobacco, tort liability, and patents. He previously worked at the Federal Trade Commission's Bureau of Economics. He had also taught marketing and consumer behavior at the business schools of the University of Maryland at College Park and Boston University. While Mr. Calfee's writings are mostly on pharmaceutical markets and FDA regulation, his academic articles and opinion pieces covered a variety of topics, from patent law and tort liability to advertising and consumer information. His books include Prices, Markets, and the Pharmaceutical Revolution (AEI Press, 2000) and Biotechnology and the Patent System (AEI Press, 2007). Mr. Calfee wrote regularly for AEI's Health Policy Outlook series. He testified before Congress and federal agencies on various topics, including alcohol advertising; biodefense vaccine research; international drug prices; and FDA oversight of drug safety.

What's new on AEI

AEI Election Watch 2014: What will happen and why it matters
image A nation divided by marriage
image Teaching reform
image Socialist party pushing $20 minimum wage defends $13-an-hour job listing
AEI on Facebook
Events Calendar
  • 20
    MON
  • 21
    TUE
  • 22
    WED
  • 23
    THU
  • 24
    FRI
Monday, October 20, 2014 | 2:00 p.m. – 3:30 p.m.
Warfare beneath the waves: The undersea domain in Asia

We welcome you to join us for a panel discussion of the undersea military competition occurring in Asia and what it means for the United States and its allies.

Tuesday, October 21, 2014 | 8:30 a.m. – 10:00 a.m.
AEI Election Watch 2014: What will happen and why it matters

AEI’s Election Watch is back! Please join us for two sessions of the longest-running election program in Washington, DC. 

Wednesday, October 22, 2014 | 1:00 p.m. – 2:30 p.m.
What now for the Common Core?

We welcome you to join us at AEI for a discussion of what’s next for the Common Core.

Event Registration is Closed
Thursday, October 23, 2014 | 10:00 a.m. – 11:00 a.m.
Brazil’s presidential election: Real challenges, real choices

Please join AEI for a discussion examining each candidate’s platform and prospects for victory and the impact that a possible shift toward free-market policies in Brazil might have on South America as a whole.

Event Registration is Closed
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.